YWP
ALNY icon

YorkBridge Wealth Partners’s Alnylam Pharmaceuticals ALNY Stock Holding History

YorkBridge Wealth Partners’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-32
Closed -$3K – 749
2018
Q2 		$3K Hold
32
– – ﹤0.01% 720
2018
Q1 		$3K Sell
32
-6
-16% -$774 ﹤0.01% 709
2017
Q4 		$5K Hold
38
– – ﹤0.01% 697
2017
Q3 		$4K Buy
+38
New +$3.24K ﹤0.01% 717

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

YorkBridge Wealth Partners's ALNY Position: Q3 2018 in Review

YorkBridge Wealth Partners sold out of Alnylam Pharmaceuticals (ALNY) in Q3 2018, closing a stake of 32 shares — an estimated $3K sold.

YorkBridge Wealth Partners first reported a position in ALNY in Q3 2017 and held it in 4 quarters. The position peaked at $5K in Q4 2017. 305 funds tracked by Wall St. Rank hold ALNY as of Q3 2018.

  • YorkBridge Wealth Partners reported no remaining Alnylam Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
  • YorkBridge Wealth Partners sold 32 Alnylam Pharmaceuticals shares in Q3 2018, an estimated $3K.
  • YorkBridge Wealth Partners first reported a position in Alnylam Pharmaceuticals in Q3 2017 and held it in 4 quarters.
  • YorkBridge Wealth Partners's Alnylam Pharmaceuticals position peaked at $5K in Q4 2017.
  • 305 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2018.

Based on YorkBridge Wealth Partners's 13F filing for Q3 2018, filed 14 Nov 2018.